ONO 4474

Drug Profile

ONO 4474

Alternative Names: ONO-4474

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Ono Pharmaceutical
  • Class Anti-inflammatories; Antirheumatics
  • Mechanism of Action Tropomyosin-related kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 15 Dec 2016 Ono Pharmaceutical plans the phase II MOTION trial for Pain (due to osteoarthritis of the knee, In adults, In the elderly) in United Kingdom, Denmark, Hungary, Spain and Poland (PO) (NCT02997696)
  • 01 Apr 2016 Ono Pharmaceutical completes a phase I trial in Pain (In volunteers) in Denmark and United Kingdom (NCT02454387)
  • 12 May 2015 Phase-I clinical trials in Pain (In the elderly, In volunteers, In adults) in Denmark (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top